rs117017463 - COL25A1

Magnitude 2.2 · 1 study on file

Reported associations

  • A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients - Unknown journal (n.d.) · Unknown authors · PubMed 36210801

    ABSTRACT: Diversity in pharmacogenomic studies is poor, especially in relation to the inclusion of black African patients. Lack of funding and difficulties in recruitment, together with the requirement for large sample sizes because of the extensive genetic diversity in Africa, are amongst the factors which have hampered pharmacogenomic studies in Africa. Warfarin is widely used in sub-Saharan Africa, but as in other populations, dosing is highly variable due to genetic and non-genetic factors. In order to identify genetic factors determining warfarin response variability, we have conducted a genome-wide association study (GWAS) of plasma concentrations of warfarin enantiomers/metabolites in sub-Saharan black-Africans. This overcomes the issue of non-adherence and may have greater sensitiv


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • warfarin dosing based on COL25A1 variant Moderate

    rs117017463 in COL25A1 is associated with altered R-warfarin plasma levels, affecting drug metabolism and clearance.

    If prescribed warfarin, inform prescriber of genotype for dosing optimization.